- Home
- ADPT vs PTEN Comparison
ADPT vs PTEN Comparison
Compare ADPT & PTEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- PTEN
- Stock Information
- Founded
- ADPT 2009
- PTEN 1978
- Country
- ADPT United States
- PTEN United States
- Employees
- ADPT N/A
- PTEN N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- PTEN Oil & Gas Production
- Sector
- ADPT Health Care
- PTEN Energy
- Exchange
- ADPT Nasdaq
- PTEN Nasdaq
- Market Cap
- ADPT 2.0B
- PTEN 2.1B
- IPO Year
- ADPT 2019
- PTEN 1993
- Fundamental
- Price
- ADPT $14.40
- PTEN $5.88
- Analyst Decision
- ADPT Strong Buy
- PTEN Buy
- Analyst Count
- ADPT 9
- PTEN 10
- Target Price
- ADPT $13.22
- PTEN $7.90
- AVG Volume (30 Days)
- ADPT 2.1M
- PTEN 8.7M
- Earning Date
- ADPT 11-06-2025
- PTEN 10-22-2025
- Dividend Yield
- ADPT N/A
- PTEN 5.43%
- EPS Growth
- ADPT N/A
- PTEN N/A
- EPS
- ADPT N/A
- PTEN N/A
- Revenue
- ADPT $205,216,000.00
- PTEN $5,019,214,000.00
- Revenue This Year
- ADPT $32.76
- PTEN N/A
- Revenue Next Year
- ADPT $15.81
- PTEN N/A
- P/E Ratio
- ADPT N/A
- PTEN N/A
- Revenue Growth
- ADPT 21.60
- PTEN N/A
- 52 Week Low
- ADPT $4.27
- PTEN $5.10
- 52 Week High
- ADPT $15.26
- PTEN $9.58
- Technical
- Relative Strength Index (RSI)
- ADPT 60.53
- PTEN 59.40
- Support Level
- ADPT $14.04
- PTEN $5.10
- Resistance Level
- ADPT $15.26
- PTEN $5.93
- Average True Range (ATR)
- ADPT 0.73
- PTEN 0.22
- MACD
- ADPT 0.05
- PTEN 0.05
- Stochastic Oscillator
- ADPT 69.09
- PTEN 96.36
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About PTEN Patterson-UTI Energy Inc.
Patterson-UTI Energy Inc is one of the substantial land rig drilling contractors in the United States. Its 2023 merger with NexTier greatly expanded its pressure pumping operations, as well, and the firm now controls nearly 20% of the North American market for drilling and completions services. The company operates under three reportable business segments: (i) drilling services, (ii) completion services, and (iii) drilling products. It also provides directional drilling services and tool rental services in united states onshore oil and gas basins.